World

Controversial US-backed vaccine trial in African newborns halted

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 21/10/2026, 17:54:24 UTC.

Briefings

A US-backed hepatitis B vaccine trial in African newborns was halted in Guinea-Bissau after researchers stated they lacked necessary governmental approval. The study, which drew global backlash, was led by Danish researcher Frederik Schaltz-Buchholzer, who confirmed the halt on Wednesday. The evidence indicates the trial will not proceed in the specific location, though broader implications for vaccine safety and international cooperation remain uncertain.

Key points

• A US-backed hepatitis B vaccine trial in African newborns was halted in Guinea-Bissau after researchers stated they lacked necessary governmental approval.
• The study, which drew global backlash, was led by Danish researcher Frederik Schaltz-Buchholzer, who confirmed the halt on Wednesday.

Context

The trial was funded by the CDC and faced global backlash, leading to a halt in Guinea-Bissau. The lead researcher confirmed the lack of approval, though the broader context of vaccine safety and international cooperation remains uncertain.

Limitations

Evidence is limited to the lead researcher's statement on Wednesday regarding the specific halt in Guinea-Bissau. The study's broader impact on global vaccine safety and international cooperation remains uncertain, and the evidence does not include additional data on the trial's outcomes or long-term effects.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 21/10/2026, 18:10:35 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeierzb643t4zasvpzv7ycpowztwbrvi2oe2f4z5wjlzyzwmlloughi